2025.01.09
On December 16, 2024, Nona Biosciences (Suzhou) Co., Ltd. ("Nona Biosciences"), a wholly-owned subsidiary of HBM Holdings Limited (stock code: 02142.HK), announced a research collaboration and license agreement to discover next-generation T-cell engagers (“TCEs”) with Candid Therapeutics, Inc. ("Candid").
Under the terms of the agreement, Nona Biosciences is eligible to receive up to USD 320 million, including an upfront payment and potential milestone payments. Candid will be responsible for all further product development.
JunHe was engaged by Nona Biosciences to review and revise the agreement. With its consistent delivery of efficient and rigorous legal services and detail-oriented and professional expertise, JunHe’s team was recognized and trusted by the client.
Partner ZHAO, Hao (Gerry) led the JunHe team.
